Literature DB >> 32641448

Increased primary care use for musculoskeletal symptoms, infections and comorbidities in the years before the diagnosis of inflammatory arthritis.

Marian van Beers-Tas1, Markus Mj Nielen2, Jos W R Twisk3, Joke Korevaar2, D van Schaardenburg4,5.   

Abstract

OBJECTIVES: Little is known about relevant events in the at-risk phase of rheumatoid arthritis before the development of clinically apparent inflammatory arthritis (IA). The present study assessed musculoskeletal symptoms, infections and comorbidity in future IA patients.
METHODS: In a nested case-control study using electronic health records of general practitioners, the frequency and timing of 192 symptoms or diseases were evaluated before a diagnosis of IA, using the International Classification of Primary Care coding system. Cases were 2314 adults with a new diagnosis IA between 2012 and 2016; controls were matched 1:2. The frequency of primary care visits was compared using logistic regression.
RESULTS: The frequency of visits for musculoskeletal symptoms (mostly of shoulders, wrists, fingers and knees) and carpal tunnel syndrome was significantly higher in IA patients vs controls within the final 1.5 years before diagnosis, with ORs of 3.2 (95% CI 2.8 to 3.5), 2.8 (95% CI 2.5 to 3.1) and 2.5 (95% CI 2.2 to 2.8) at 6, 12 and 18 months before diagnosis, respectively. Also, infections (notably of the genital and urinary tracts), IA-comorbidities and chronic diseases were more prevalent in cases than controls, but more evenly spread out over the whole 6-year period before IA. A decision tree was created including all symptoms and diseases.
CONCLUSION: There was an increased frequency of primary care visits for musculoskeletal symptoms, infections and comorbidities prior to the diagnosis of IA. This diverging trend is present for 4-6 years, but becomes statistically significant 1.5 years before the diagnosis. Validation of these results is warranted. © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.

Entities:  

Keywords:  Autoantibodies; Inflammation; Rheumatoid Arthritis

Mesh:

Year:  2020        PMID: 32641448      PMCID: PMC7425115          DOI: 10.1136/rmdopen-2019-001163

Source DB:  PubMed          Journal:  RMD Open        ISSN: 2056-5933


  45 in total

1.  The birth of the International Classification of Primary Care (ICPC). Serendipity at the border of Lac Léman.

Authors:  Henk Lamberts; Maurice Wood
Journal:  Fam Pract       Date:  2002-10       Impact factor: 2.267

2.  Cardiovascular risk in rheumatoid arthritis and diabetes: how does it compare and when does it start?

Authors:  Michael T Nurmohamed; George Kitas
Journal:  Ann Rheum Dis       Date:  2011-03-30       Impact factor: 19.103

3.  Identifying arthralgia suspicious for progression to rheumatoid arthritis.

Authors:  Kulveer Mankia; Jackie Nam; Paul Emery
Journal:  Ann Rheum Dis       Date:  2016-12-08       Impact factor: 19.103

4.  Association between psoriasis, psoriatic arthritis and gout: a nationwide population-based study.

Authors:  S C-S Hu; C-L Lin; H-P Tu
Journal:  J Eur Acad Dermatol Venereol       Date:  2018-11-15       Impact factor: 6.166

5.  Delays in assessment of patients with rheumatoid arthritis: variations across Europe.

Authors:  Karim Raza; Rebecca Stack; Kanta Kumar; Andrew Filer; Jacqueline Detert; Hans Bastian; Gerd R Burmester; Prodromos Sidiropoulos; Eleni Kteniadaki; Argyro Repa; Tore Saxne; Carl Turesson; Herman Mann; Jiri Vencovsky; Anca Catrina; Aikaterini Chatzidionysiou; Aase Hensvold; Solbritt Rantapää-Dahlqvist; Alexa Binder; Klaus Machold; Brygida Kwiatkowska; Adrian Ciurea; Giorgio Tamborrini; Diego Kyburz; Christopher D Buckley
Journal:  Ann Rheum Dis       Date:  2011-08-07       Impact factor: 19.103

Review 6.  Prediction of future rheumatoid arthritis.

Authors:  Samina A Turk; Marian H van Beers-Tas; Dirkjan van Schaardenburg
Journal:  Rheum Dis Clin North Am       Date:  2014-09-02       Impact factor: 2.670

7.  How do general practitioners identify inflammatory arthritis? A cohort analysis of Dutch general practitioner electronic medical records.

Authors:  Elize C Newsum; Margot W M de Waal; Hanna W van Steenbergen; Jacobijn Gussekloo; Annette H M van der Helm-van Mil
Journal:  Rheumatology (Oxford)       Date:  2016-01-07       Impact factor: 7.580

8.  Prevalence of chronic diseases at the onset of inflammatory arthritis: a population-based study.

Authors:  Jennie Ursum; Joke C Korevaar; Jos W R Twisk; Mike J L Peters; François G Schellevis; Micheal T Nurmohamed; Mark M J Nielen
Journal:  Fam Pract       Date:  2013-07-20       Impact factor: 2.267

Review 9.  Arthritis susceptibility and the gut microbiome.

Authors:  Veena Taneja
Journal:  FEBS Lett       Date:  2014-05-27       Impact factor: 4.124

10.  Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA).

Authors:  Maxime Dougados; Martin Soubrier; Anna Antunez; Peter Balint; Alejandro Balsa; Maya H Buch; Gustavo Casado; Jacqueline Detert; Bassel El-Zorkany; Paul Emery; Najia Hajjaj-Hassouni; Masayoshi Harigai; Shue-Fen Luo; Reka Kurucz; Gabriel Maciel; Emilio Martin Mola; Carlo Maurizio Montecucco; Iain McInnes; Helga Radner; Josef S Smolen; Yeong-Wook Song; Harald Erwin Vonkeman; Kevin Winthrop; Jonathan Kay
Journal:  Ann Rheum Dis       Date:  2013-10-04       Impact factor: 19.103

View more
  2 in total

Review 1.  Preclinical Autoimmune Disease: a Comparison of Rheumatoid Arthritis, Systemic Lupus Erythematosus, Multiple Sclerosis and Type 1 Diabetes.

Authors:  Giulia Frazzei; Ronald F van Vollenhoven; Brigit A de Jong; Sarah E Siegelaar; Dirkjan van Schaardenburg
Journal:  Front Immunol       Date:  2022-06-30       Impact factor: 8.786

2.  Prioritising referrals of individuals at-risk of RA: guidance based on results of a 10-year national primary care observational study.

Authors:  Leticia Garcia-Montoya; Jacqueline L Nam; Laurence Duquenne; Catalina Villota-Eraso; Andrea Di Matteo; Collette Hartley; Kulveer Mankia; Paul Emery
Journal:  Arthritis Res Ther       Date:  2022-01-18       Impact factor: 5.156

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.